Real improvements have been made, and performance has compared quite favourably with European countries of comparable development, but there are two particular causes for concern: a) the rate of improvement in avoidable cancer mortality has fallen since 1999, at odds with trends since 1979; b) avoidable mortality from circulatory disease remains very high.